Loss of corticospinal tract integrity in early MS disease stages

Objective: We investigated corticospinal tract (CST) integrity in the absence of white matter (WM) lesions using diffusion tensor imaging (DTI) in early MS disease stages. Methods: Our study comprised 19 patients with clinically isolated syndrome (CIS), 11 patients with relapsing-remitting MS (RRMS), and 32 age- and sex-matched healthy controls, for whom MRI measures of CST integrity (fractional anisotropy [FA], mean diffusivity [MD]), T1- and T2-based lesion load, and brain volumes were available. The mean (SD) disease duration was 3.5 (2.1) months, and disability score was low (median Expanded Disability Status Scale 1.5) at the time of the study. Results: Patients with CIS and RRMS had significantly lower CST FA and higher CST MD values compared with controls. These findings were present, irrespective of whether WM lesions affected the CST. However, no group differences in the overall gray or WM volume were identified. Conclusions: In early MS disease stages, CST integrity is already affected in the absence of WM lesions or brain atrophy.

[1]  C. Zimmer,et al.  Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity , 2016, Journal of Neurology.

[2]  Heidi Johansen-Berg,et al.  A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology , 2012, Brain : a journal of neurology.

[3]  M. Lowe,et al.  Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study , 2014, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[4]  A. Phillips,et al.  The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records , 2017, Current medical research and opinion.

[5]  E. Rostrup,et al.  Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI☆☆☆ , 2013, NeuroImage: Clinical.

[6]  Frederik Barkhof,et al.  Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. , 2009, Archives of neurology.

[7]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[8]  R. Henry,et al.  Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  M. Barry,et al.  Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. , 2016, Multiple sclerosis and related disorders.

[10]  G J Barker,et al.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.

[11]  M. Ron,et al.  Cognitive impairment in relapsing—remitting multiple sclerosis can be predicted by imaging performed several years earlier , 2008, Multiple sclerosis.

[12]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[13]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[14]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[15]  À. Rovira,et al.  Predictive value of early brain atrophy on response in patients treated with interferon β , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[16]  ichard,et al.  AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS , 1998 .

[17]  S. Amor,et al.  Preactive lesions in multiple sclerosis , 2009, Current opinion in neurology.

[18]  Massimo Filippi,et al.  Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. , 2003, AJNR. American journal of neuroradiology.

[19]  Ludwig Kappos,et al.  The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options , 2016, PloS one.

[20]  Frederik Barkhof,et al.  Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study , 2015, Journal of Neurology.

[21]  F. Barkhof,et al.  What explains gray matter atrophy in long-standing multiple sclerosis? , 2014, Radiology.

[22]  Darin T. Okuda,et al.  Early CNS neurodegeneration in radiologically isolated syndrome , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[23]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[24]  D. Okuda,et al.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis , 2016, Neurotherapeutics.

[25]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[26]  M. Sormani,et al.  Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[27]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  P. Grant,et al.  Diffusion Tensor Analysis of Pediatric Multiple Sclerosis and Clinically Isolated Syndromes , 2013, American Journal of Neuroradiology.

[29]  Michael Wall,et al.  MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group , 2002, Neurology.

[30]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[31]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[32]  D. Reich,et al.  Longitudinal changes in diffusion tensor–based quantitative MRI in multiple sclerosis , 2011, Neurology.

[33]  Chunshui Yu,et al.  Diffusion tensor tractography-based group mapping of the pyramidal tract in relapsing-remitting multiple sclerosis patients. , 2007, AJNR. American journal of neuroradiology.

[34]  Peter A. Calabresi,et al.  Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis , 2007, NeuroImage.

[35]  K Ambarki,et al.  Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis , 2013, American Journal of Neuroradiology.

[36]  C. Tempelmann,et al.  Monte Carlo-based diffusion tensor tractography with a geometrically corrected voxel-centre connecting method , 2009, Physics in medicine and biology.

[37]  G. Comi,et al.  MRI quantification of gray and white matter damage in patients with early–onset multiple sclerosis , 2006, Journal of Neurology.

[38]  P. Pantano,et al.  DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications , 2013, Multiple sclerosis international.

[39]  Maija E. Rossi,et al.  Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera , 2013, Multiple sclerosis international.

[40]  D. Reich,et al.  Quantitative characterization of the corticospinal tract at 3T. , 2006, AJNR. American journal of neuroradiology.

[41]  Marco Bozzali,et al.  Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. , 2010, Radiology.